



Decisions about deep brain stimulation 
therapy in Parkinson’s disease
Decisões a respeito da terapia com estimulação cerebral profunda na doença de Parkinson
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Parkinson’s disease (PD), a hypokinetic movement disorder 
characterized by the classic tetrad of bradykinesia, rest tremor, 
plastic rigidity, and postural disturbances1,2, is a neurodegener-
ative disorder with an increasing impact on the Brazilian social 
and healthcare system, mirroring known demographic-epide-
miological changes such as aging of the population and widen-
ing of the apex of the age pyramid3,4. Considering a prevalence 
of 3.3% in those aged 65 or older in the Brazilian population5, 
the country has at least 200,000 patients living with the disor-
der, a definitive challenge to the public health system.
Parkinson’s disease has effective symptomatic treatment 
options that have a positive, but rather limited, effect on 
minimizing long-term functional motor disability, including 
levodopa, dopaminergic agonists, catechol-O-methyltrans-
ferase inhibitors, anticholinergics, monoamine oxidase B 
inhibitors, and amantadine6.
However, most, if not all, PD patients are expected to 
develop complications related to disease progression and 
chronic use of the aforementioned therapies, hindering clini-
cal management and limiting therapeutic options. The two 
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ABSTRACT
Parkinson’s disease can be treated surgically in patients who present with motor complications such as fluctuations and dyskinesias, or 
medically-refractory disabling tremor. In this review, a group of specialists formulated suggestions for a preoperative evaluation protocol 
after reviewing the literature published up to October 2017. In this protocol, eligibility and ineligibility criteria for surgical treatment were 
suggested, as well as procedures that should be carried out before the multidisciplinary therapeutic decisions. The review emphasizes the 
need to establish “DBS teams”, with professionals dedicated specifically to this area. Finally, surgical target selection (subthalamic nucleus 
or globus pallidus internus) is discussed briefly, weighing the pros and cons of each target.
Keywords: Parkinson disease; deep brain stimulation; reference standards; basal ganglia; neurosurgical procedures.
RESUMO
A doença de Parkinson pode ser tratada cirurgicamente em pacientes que desenvolveram complicações motoras, como flutuações 
e discinesias, ou tremores refratários ao uso de medicação. Nesta revisão, um grupo de especialistas formulou sugestões para um 
protocolo de avaliação pré-operatória, depois de revisar a literatura publicada até outubro de 2017. Neste protocolo, são sugeridos 
critérios de elegibilidade e inadmissibilidade para tratamento cirúrgico, bem como procedimentos que devem ser realizados antes das 
decisões terapêuticas multidisciplinares. A revisão enfatiza a necessidade de estabelecer “equipes de DBS”, com profissionais dedicados 
especialmente a esta área. Ao final, a seleção do alvo cirúrgico (núcleo subtalâmico ou globo pálido interno) é discutida brevemente, 
ponderando prós e contras de cada escolha.
Palavras-chave: doença de Parkinson; estimulação cerebral profunda; padrões de referência; gânglios da base; procedimentos 
neurocirúrgicos.
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most frequent of these complications, levodopa-induced 
dyskinesias and motor fluctuations, may have a significant 
impact on functionality and quality of life in the mid and late 
stages of PD.
Functional neurosurgery in Parkinson’s disease
Among the limited number of strategies used in the man-
agement of some of these long-term motor complications, 
surgical treatment with stereotactic implanting of elec-
trodes for deep brain stimulation (DBS) has gained consider-
able importance over the past few decades. Since its pioneer 
development by Benabid’s group in the 1980s7, the technique 
has evolved dramatically and revolutionized the treatment of 
PD and other movement disorders.
Compared to classic lesional procedures such as thala-
motomy and pallidotomy, DBS has a few advantages, as it 
is reversible and adjustable to address problems related to 
adverse effects and disease progression per se. Currently, an 
estimated 160,000 DBS implant procedures have been per-
formed worldwide8, consolidating its effectiveness. The pro-
cedure, however, has caveats, limitations, and is well rec-
ognized as potentially harmful if indicated in the wrong 
timing and clinical scenario9. Therefore, despite the encour-
aging overall experience, only about 20-30% of patients with 
PD meet an adequate profile to be considered good candi-
dates for DBS and an even smaller proportion will eventually 
undergo the surgical procedure10. In other words, appropri-
ate patient selection is critical, and surgery must be per-
formed during a relatively restricted window of time during 
the course of disease, that is, at a time in which it can provide 
gain (or “regain”) of motor functionality while social adapta-
tion is still possible11.
This review aims to provide literature-based clues about 
indications, contraindications, risks, benefits and their cave-
ats, with the objective of guiding clinicians in the best use 
of these powerful techniques, especially avoiding inappro-
priate surgeries and expectations. We also aim to stimulate 
the creation of a formal reference protocol as a tool for uni-
form decision-making regarding the indication of these pro-
cedures in PD.
METHODS
A literature search was performed using the terms 
“Parkinson”, “Deep Brain Stimulation”, “Randomized Trial”, 
“Subthalamic nucleus”, “GPi”, “STN”, and “meta-analysis” 
in the MEDLINE database, in the period between 1995 and 
2014. After an initial reading of 118 abstracts from clinical 
trials, six randomized and controlled trials with a satisfac-
tory methodological design were selected. Additional refer-
ences (two clinical trials) were added after an active search in 
the bibliographical citations of the expert consensuses and 
meta-analyses.
A working group formed by six neurologists, two neuro-
surgeons and one neuropsychologist, all experienced in PD 
and DBS surgery, met formally on two occasions (February 
and March, 2014), to discuss current scientific evidence, and 
attempt to adapt these to national and regional realities. The 
protocol was further addressed in video-conferences, e-mail 
discussions between the members, and further at the Deep 
Brain Stimulation International Academy course, hosted 
by Toronto Western Hospital (in October, 2017), after being 
updated with current literature.
RESULTS
The results of the literature search that supports the sug-
gestions of our study group are described in Table 1 (random-
ized and controlled studies), Table 2 (meta-analyses) and Table 3 
(consensus of experts). A total of eight randomized controlled tri-
als, seven meta-analyses (or systematic reviews), and six consen-
suses of specialists were analyzed and included in the protocol.
Table 1 describes year and authorship of the study (to pro-
vide information from an historical point of view), number of 
patients, period of follow-up, the centers’ geographic location, 
duration since PD diagnosis, surgical target [internal globus 
pallidus (GPi) or subthalamic nucleus (STN)], in addition to 
a summary of results in terms of efficacy and safety. Table 
2 shows data on the meta-analyses and systematic reviews 
published over the last 22 years, also organized from an his-
torical perspective, compiling the results of motor functional 
assessments and quality of life after surgery. Table 3 summa-
rizes published recommendations and guidelines from lead-
ing national and international neurology and movement dis-
orders specialists’ associations concerning indications and 
contraindications for functional surgery in PD.
From the analysis of these data, suggestions for a clinical 
eligibility protocol for functional surgery in PD are described.
Suggested criteria for surgical eligibility
1) High level of certainty about the diagnosis of idiopathic 
PD using the Queen Square Brain Bank diagnostic criteria33 
or the new international Parkinson and Movement Disorders 
Society (MDS) criteria2. An alternative diagnosis of atypical 
or secondary parkinsonism (Lewy body dementia, vascular 
parkinsonism, progressive supranuclear palsy, multiple sys-
tems atrophy, or other) should be carefully excluded;
2) Clinical progression for a minimum of four years is 
additionally useful for improving the certainty of a clinical 
diagnosis of idiopathic PD;
3) Confirmation of levodopa responsiveness using the 
levodopa challenge test, which is described in detail in a 
separate section of this manuscript. Improvement of at least 
30-40% is required in Part III of the Unified Parkinson Disease 
Assessment Scale (UPDRS)34 or MDS-UPDRS35, the most 
recent version of the scale;
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Table 1. Randomized controlled trials evaluating DBS in Parkinson’s disease.
Author, year N Follow-up Target Mean disease duration Center Clinical outcomes
Anderson et al.12 23 12 m STN or GPi 15.6 y (STN); 10.2 y (GPi) USA
STN DBS patients tend to remain on lower 
levodopa dosage (-38%), but have shown more 
cognitive and behavioral side effects
Deuschl et al.13 156 6 m
Bilateral STN 
(n = 78) vs. best 
medical therapy 
13.0 y Germany and Austria
STN DBS: 9.5 pts improvement in PDQ-39 and 
19.6 improvement in UPDRS-III. One fatal brain 
hemorrhage.
Schüpbach et al.14 20 18 m
Bilateral STN 
(n = 10) vs. best 
medical therapy
6.8 y France
24% improvement in QoL; -69% severity of motor 
symptoms in off time; -83% motor complications; 
-57% reduction in levodopa dosage
Weaver et al.15 255 6 m
STN (n = 60); GPi 
(n = 61); best medical 
therapy (n = 134)
12.4 y USA
Longer ON time without dyskinesia (+4.6 hours 
a day); similar between GPi and STN DBS; 
worse verbal fluency in STN DBS
Williams et al.16 366 12 m
Bilateral STN (n = 183) 
vs. best medical 
therapy (n = 183)
11.4 y United Kingdom
Improved dyskinesia and daily ON time; 5 
pts improvement in PDQ-39-SI; 19% serious 
adverse effects
Follett et al.17 299 24 m STN (n = 147) or GPi (n = 152)
11.1y (STN); 
11.4 y (GPi) USA
GPi and STN DBS similar efficacy. STN DBS: 
lower dose of dopaminergic agents, higher 
risk of depression and reduced visuomotor 
processing speed;
Okun et al.18 136 3 m
STN: immediate 
(n = 131) or delayed 
(n = 35) stimulation
12.0 y USA
+2h50 daily ON time; UPDRS-III: improvement 
(39%);4% surgical site infection; 3% 
intracranial hemorrhage;
Schüpbach et al.19 251 24 m
Bilateral STN (n = 124) 
vs. medical therapy 
(n = 127)
7.5 y Germany and France
Improved motor disability, motor 
complications, daily life activities and ON time 
without troublesome dyskinesia.
STN: subthalamic nucleus; GPi: internal globus pallidus; PDQ-39-SI: 39-item Parkinson’s disease questionnaire summary index.
Table 2. Systematic reviews and meta-analyses of clinical studies evaluating deep brain stimulation in Parkinson’s disease.
Authors, year Number of studies included Conclusions
Kleiner-Fisman et al.20 22 studies
UPDRS-II: 13.3 pts improvement;
UPDRS-III: 27.55 pts improvement;
Mean reduction of LED: 55.9%
Mean dyskinesia improvement: 69%;
Mean OFF time reduction: 68%;
PDQ-39: 34.5% improvement;
Most severe adverse effect: intracranial hemorrhage 3.9%
Andrade et al.21 22 studies (n = 327)
GPi: 19 pts improvement in UPDRS-III;
Best programming parameters for 50% improvement in UPDRS-III: amplitude between 
2.0-3.5V, pulse width between 70-300 µs and frequency: 100-190Hz.
Sharma et al.22 5 studies
Improved motor function and QoL. Higher incidence of side effects. Studies limited due 
to design and sample size. Surgery is an option after best medical therapy (individual 
risk/benefit ratio shall be addressed)
Volkmann et al.23
6 class I studies; Consistent evidence of benefit for dyskinesias and motor fluctuations. Evidence was considered insufficient for apomorphine infusion and levodopa duodenal pump.
4 class II studies; Safe procedure in cognitively intact patients.
comparison with best 
medical therapy Dementia must be an exclusion criterion.
Perestelo-Pérez et al.24 6 randomized controlled trials (n = 1184)
DBS improved QoL, motor symptoms and disability. Strong effects for OFF motor signs 
and disability. Reduces levodopa daily dosing and motor complications. Moderate 
effect for ON motor signs, time without disability in ON.
Liu et al.25
6 trials (n = 563), 
comparing GPi and STN 
as targets
STN and GPi DBS equally improved UPDRS part II and III.
GPi DBS: greater improvement in depression scores.
Mansouri et al.26
13 studies (6 original 
trial cohorts), with 
follow-up for 6, 12, 24 
and 36 months
Motor scores and QoL: long-term benefits are similar between both targets (GPi or STN);
STN DBS: lower medication dosage;
GPi DBS: better outcomes in Beck Depression Inventory.
UPDRS: Unified Parkinson Disease Assessment Scale; LED: Levodopa equivalent dose; PDQ-39: Parkinson’s Disease Questionnaire; STN: subthalamic nucleus; 
GPi: internal globus pallidus; DBS: deep brain stimulation. 
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Table 3. Expert consensuses on functional neurosurgery in Parkinson’s disease.






Response in levodopa challenge test 
is an outcome predictor for STN DBS 
(Evidence level B).
Not addressed
STN DBS could be offered 
as a therapeutic option to 
improve motor function and 
reduce dyskinesia, motor 









Defined PD diagnosis; levodopa 
responsive; significant functional 
impairment;
Age does not predict 




UPDRS-III > 30 in OFF time and 
UPDRS-III < 30 in ON time;
Trials have excluded 
patients with 
comorbidities.
STB DBS could impair verbal 
fluency, induce psychiatric 





Individualized decision; evaluate 
interpersonal relations, work situation, 
expectations;
Active depression, 
suicidal ideation history, 
psychosis, bipolar 
disorder, medication 




evaluation is mandatory 
before surgery.
  Disease progression for, at least, 5 years.  
Vim thalamic DBS could be 
considered if tremor is more 
important than rigidity or 
bradykinesia.
Bronstein et al.29 Multi-institutional Diverse
PD diagnosis for, at least, 5 years; Dementia;
-
dyskinesia, tremor or fluctuations 
refractory to best medical therapy.
Active psychiatric 
disorder
> 30% improvement in UPDRS-III in 







Diverse Not addressed Not addressed
STN DBS is effective for 
dyskinesia and motor 
fluctuation;
GPi DBS is effective for 
motor symptoms, as an 
adjunct to levodopa, and to 







Defined PD diagnosis, lasting at least 
5 years; Dementia;
Class B recommendation
Levodopa-responsive (> 25-50% 





Unsatisfactory symptom improvement 




Easy access to the medical centre; Significant ventricle enlargement.







Defined PD; severe motor fluctuations, 
unpredictable ON-OFF, dyskinesia*;
Exclude patients with 
advanced age (>70 y);
STN DBS: level A for reducing 
dopaminergic drug dosage;
* There was no reference to disease 
duration, levodopa response.
Major cognitive or 
psychiatric disorder.
GPi DBS: level A for reducing 
severe dyskinesias;
   
STN or GPi DBS: level A for 
treating severe dyskinesia or 
motor fluctuations;
   
Slight decline in executive 
functions may occur (Stroop 
test and verbal fluency).
STN: subthalamic nucleus; DBS: deep brain stimulation; MRI: magnetic resonance imaging; GPi: internal globus pallidus; UPDRS-III: Unified Parkinson’s Disease 
Rating Scale Part III.
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4) Exceptions to the need for levodopa responsiveness 
include patients with severe disabling resting tremor, resis-
tant to dopaminergic therapy. In these patients, the symp-
tomatic benefit is likely, regardless of the levodopa challenge 
test response;
5) Disabling motor complications of levodopa therapy (dyski-
nesias or motor fluctuations), not responsive to the optimization 
of drug treatment, according to guideline recommendations31. 
This definition applies, for example, to patients with 
severe dyskinesias, OFF time that lasts more than 25% of the 
awake time, OFF periods with disabling symptoms (e.g., pain, 
dystonia, panic attacks, autonomic reactions), or unpredict-
able OFFs. Young patients who are intolerant to dopaminer-
gic agents (due to nausea or emesis despite adequate symp-
tomatic therapy), an infrequent situation, are also cited as a 
group who could benefit from surgery36.
6) The clinical evaluation should be performed in a spe-
cialized multidisciplinary Movement Disorders service37;
7) Functional disability must be defined by scales [e.g., 
Schwab & England Functional Scale38, PDQ-3939];
8) The following attributes give support to the surgical eli-
gibility: young age onset, severe tremor, need to reduce medi-
cations, nocturnal akinesia. 
Suggested absolute criteria for ineligibility
1) Unstable clinical comorbidities (e.g., coronary artery dis-
ease, active infection, significant subcortical arteriosclerotic 
encephalopathy, other disabling cerebrovascular diseases, malig-
nancy or organ failure associated with reduced life expectancy)28;
2) Major psychiatric or neurobehavioral disorders (e.g., pri-
mary psychotic disorder, uncontrolled bipolar disorder, major 
or drug-resistant depressive disorder, psychoactive substance 
abuse, severe personality disorder with chances of interfering 
with tolerance, understanding or adherence to treatment);
3) Definitive dementia29;
4) Doubtful diagnosis of PD29;
5) Significant ventricular enlargement or cerebral atrophy 
in magnetic resonance imaging (MRI)28;
6) Severe axial symptoms resistant to treatment with 
levodopa (dysarthria, dysphagia, postural instability or gait 
disturbances)40;
7) Inability to provide informed consent;
8) Social or geographic difficulties in gaining access to the 
center, for follow-up visits and programming of the stimulator;
9) Absence of functional disability;
10) Inadequate or fragile social support ( family or caregivers).
Suggested relative criteria for ineligibility
1) Any cognitive disorder that may interfere with adequate 
understanding about the treatment procedures (surgery and 
follow-up), or potential for worsening or interference with 
daily activities after surgery; significant impairment of seman-
tic or phonemic verbal fluency in the preoperative evaluation;
2) Untreated, unstable or recurrent major depression;
3) In general, there is a reluctance to recommend surgery 
in patients of advanced age (defined as over 70), as the risk/
benefit ratio is less favorable due to cumulative comorbidi-
ties and cognitive burden37;
4) UPDRS Part III with a score lower than 30/108 in 
“defined OFF”, representing a low functional disability in the 
absence of significant therapeutic effect of levodopa28;
5) UPDRS Part III with a score greater than 30/108 on “defi-
nite ON”, representing an unsatisfactory response to levodopa 
in the period with strongest effect (except when high scores 
are driven for the most part by treatment resistant tremor)28;
6) DBS is not usually recommended if the disability is 
related to symptoms that are levodopa-unresponsive, such as 
gait, postural instability, and dysarthria, (except for tremor)28.
Controversial issues about ineligibility criteria
Impulse control disorders, manifested in the extreme form 
as the “dopaminergic dysregulation syndrome”, are controver-
sial relative ineligibility criteria. The outcomes for impulse con-
trol disorders and dopaminergic dysregulation syndrome after 
DBS are unpredictable: there are reports of ameliorated or wors-
ened symptoms, and even the onset of novel impulse control 
disorders41,42,43,44,45. These so-called hyperdopaminergic behav-
ioral manifestations could denote a background of susceptibility 
for psychiatric disorders and, even though some have reported 
good outcomes44,45, these effects may not materialize in the long-
term41,42,43. In our experience, their presence should be viewed as 
a warning sign, and a case-by-case analysis is advised, taking 
into consideration other cognitive and behavioral comorbidities.
Suggested mandatory procedures before the 
evaluation of the multidisciplinary team, regarding 
candidacy for surgery
Levodopa challenge test
General guidelines for test performance
1) Patient should start the test in a “definite OFF” con-
dition, i.e., after withdrawal of antiparkinsonian medication 
for at least 12 hours; this interval should be adapted as some 
patients may require longer withdrawal periods to achieve 
the definite OFF state.
2) The “definite ON” condition must be achieved during 
the test, i.e., the patient and the physician must agree that, 
after the administration of levodopa, the best possible func-
tional state has been achieved;
3) Levodopa dosing at the test: either the patient’s regular dose 
(according to the CAPSIT-PD protocol)46 or supra-threshold dos-
age (1.5 times the usual effective dose or usual effective dose + 50 
mg, or usual effective dose + 100 mg if the patient is on a dopami-
nergic agonist) can be used, according to the service’s preference;
4) Assessment: scales used for the grading the motor 
signs of parkinsonism and staging of PD, such as the Part III 
of the UPDRS34 or MDS-UPDRS35, Hoehn & Yahr scale and, if 
possible, a dyskinesia scale;
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5) It is desirable to record the test on video for discussion 
at a consensual multidisciplinary experts meeting.
Important observation: the ideal candidate is a patient 
who is severely disabled in the OFF condition and indepen-
dent in the ON condition, with a difference of at least 30% in 
the UPDRS Part-III scores; this is calculated by dividing the 
difference between the OFF and ON scores by the OFF score. 
The result is then multiplied by 100. 
Brain magnetic resonance imaging 
Suggested minimum protocol of imaging sequences
1) Volumetric (three-dimensional thin slice acquisi-
tion) MRI slices with emphasis on the basal ganglia: T1- and 
T2-weighted images;
2) A specific search should be done to rule out findings 
that suggest an alternative diagnosis (atypical parkinsonism) 
or co-morbidities. These findings include: a marked small 
vessel disorder of the subcortical white matter or brainstem, 
hot cross bun sign, putaminal rim sign, morning glory sign, 
significant atrophy of the midbrain tectum, diffuse cortical 
atrophy, hydrocephalus, caudate atrophy. Specific sequences 
that emphasize the basal ganglia, substantia nigra, subcorti-
cal white matter and midbrain should be used;
3) Patients who present with significant cerebral atrophy, 
significantly enlarged ventricles, structural lesions, or other 
findings that, in keeping with atypical clinical findings, sug-
gest the diagnosis of a secondary or atypical parkinsonism, 
should not be submitted for DBS.
Some DBS centers (e.g. University of Florida) have advo-
cated the use of a novel 3T volumetric (thin-slice, 1 mm thick) 
MRI sequence, named FGATIR ( fast gray matter acquisition 
T1 inversion recovery), which could provide a sharper delin-
eation of the contour of the basal ganglia nuclei47. 
Neuropsychological and psychiatric preoperative 
assessment
The purpose of the cognitive assessment in the preoperative 
evaluation is to provide a cognitive diagnosis (PD with intact cog-
nition, PD with mild cognitive impairment [PD-MCI] or PD with 
dementia [PDD]), allowing a rough prediction of the risk of future 
cognitive decline and guidance in planning surgical target selec-
tion. A comprehensive cognitive evaluation is advised, ideally 
including two tests for each of five cognitive domains (attention 
and working memory, executive functions, memory, language 
and visuospatial function), as proposed by level II MDS crite-
ria for PD-MCI and PDD48,49. The tests must have local (prefer-
ably national) psychometric validation. Relying only on screening 
instruments is not recommended, because they are not accurate 
enough to identify high- and low-risk groups. The screening tests 
also do not permit accurate identification of the subtypes of cog-
nitive impairment and information of peculiar prognostic impli-
cations, as shown in previous cohort studies50,51,52.
A psychiatrist experienced in PD is an important mem-
ber of the multidisciplinary group. Psychiatric presurgical 
assessment and post-DBS follow-up is essential for the iden-
tification and management of anxiety disorders, depression, 
apathy, and behavioral issues such as dopamine dysregulation 
syndrome and impulse control disorders. Another psychiat-
ric facet of this population is described well by paraphras-
ing Dr. Mateusz Zurowski, the neuropsychiatrist affiliated 
with the Neuromodulation Service of the Toronto Western 
Hospital: good outcomes in DBS cases might be viewed as 
a “sudden transition for individuals in the midst of coping 
with a degenerative disorder with progressively diminishing 
resources”. That sentence more than suffices to ascertain the 
importance of this kind of mental care in DBS candidates, 
reminding us that even good outcomes can be a source of 
uneasiness when adapting to a sudden change in self-image 
and the individuals’ role in their families and society.
What are the purposes and benefits of the 
multidisciplinary approach for surgical indication?
A multidisciplinary DBS team is a group of professionals 
with technical expertise, dedicated to the preoperative, intra-
operative and postoperative phases of this therapeutic tech-
nique. In most centers, it comprises neurologists (specialized 
in movement disorders and experienced in DBS program-
ming), neurosurgeons, neuropsychologists, neuropsychiatrists, 
nurses, and administrative assistants. Their roles vary from 
center to center and are not formally established in guidelines, 
but should cover essential aspects including the adequate 
selection of candidates for surgery, arrangement and perfor-
mance of all preoperative assessments and the surgery per se, 
immediate postoperative (including initial programming) and 
long-term care and device management53,54. We argue that the 
special dedication to these functions minimizes treatment fail-
ures and optimizes care for long-term troubleshooting55. Also, 
the existence of this group of professionals and their interac-
tion is only possible in a center with a special interest, commit-
ment and expertise in these surgical techniques.
Selection of the surgical target
The topic of target selection has created numerous con-
troversies over the years. It is generally accepted that GPi DBS 
has a direct effect on dyskinesia reduction, while STN DBS may 
have a similar but indirect effect, dependent on the reduction of 
the total dopaminergic medication daily dosing (Figure). Also, 
in general, GPi DBS is not rewarded by significant medication 
reduction but allows flexibility in the medication regimen55.
Most of the motor improvement is expected for non-axial 
signs and symptoms, with attenuation of motor fluctuations. 
The effect on speech can be negative, especially due to hypo-
phonia after STN DBS. Cognition, if unimpaired, should not suf-
fer a negative or positive influence, but might decline in those 
with baseline impairments56. Carefully selected patients with 
MCI may be candidates for DBS surgery; in these cases, the pre-
ferred target should be the GPi, which seems to be safer, with 
the caveat that conclusive studies confirming this impression 
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are still lacking. Yet, even in these situations, case-by-case dis-
cussions are essential. If MCI is characterized by a profile con-
sidered atypical for PD or is felt to be progressive, the decision 
for surgery should be strongly questioned, regardless of target.
In terms of motor effectiveness, a few variables were com-
pared in a recent meta-analysis of the outcomes between the 
two targets after 36 months follow-up26. Improvements in motor 
symptoms during the “on-medication” period, was not different 
between STN and GPi DBS, however, reduction of the impact 
of motor symptoms during the “off-period” and the total daily 
medication dosage were more significant for STN DBS. The GPi 
DBS procedure showed a trend towards stronger dyskinesia 
reduction. Off-period motor symptoms and daily functioning 
were better for STN DBS, when compared with GPi, in a ran-
domized, controlled trial with three years follow-up57.
The trials that evaluated depression scores (with the Beck 
Depression Inventory) have shown better outcomes for GPi 
DBS17,25,58,59. As the STN is a smaller target, it is more suscep-
tible to slight electrode misplacements, which could produce 
stimulation in structures that have a strong connection to 
the limbic system. The anatomic configuration of the nucleus 
and its connections could, thus, explain these adverse effects 
over mood and behavior26,60.
The effects of DBS over impulse control disorders are less 
predictable, with previous descriptions of resolution (partial or 
complete) and also emergence of new impulse control disor-
ders41,42,43,44,45. The existence of impulse control disorders should 
be addressed in the presurgical assessments and attempts to 
treat these symptoms should be done before surgery61. Binge 
eating has been related to STN DBS and could explain, at least 
partially, the weight gain observed following surgery62. In gen-
eral, the presence of impulse control disorders and dopaminer-
gic dysregulation syndrome should be seen as clues to the exis-
tence of potential susceptibility to psychopathology.
Regarding axial symptoms, there is no certainty about 
differences between the two targets in short- or long-term 
follow-ups. In theory, impairments in speech and swallow-
ing could be induced more frequently by STN DBS, due to 
its proximity to corticobulbar fibers, but the cited meta-anal-
ysis and an additional systematic review did not confirm 
this association26,63. Some features of gait, such as anticipa-
tory postural adjustments and freezing of gait, could improve 
with surgery, but postural instability and falls are less likely to 
improve, and might, in fact, worsen after DBS40.
As a general principle, the STN is a target that seems 
to be superior in controlling bradykinesia and rigidity, off-
period dystonia, and has a better economic profile (lower 
charge density is needed, with could spare equipment bat-
teries, and allow lower medication dosage)17,64,65. On the 
other side, STN DBS may have a less favorable profile when 
it comes to cognitive and behavioral adverse effects. It cor-
relates with worsened attention, working memory and pro-
cessing speed, verbal fluency and cognitive flexibility, and 
possibly with faster decline in memory tests56,58,59,66. The GPi 
DBS seems to be superior in controlling dyskinesias and 
on-period dystonia, and could also be useful in a unilat-
eral-only approach in patients with highly asymmetric PD 
features. Mood and apathy scores seem to be less affected 
when the target is the GPi, probably due to a less significant 
dopaminergic medication dosage reduction11.
The target selection should take the patient profile into 
account (Table 4) and ideally be decided in a multidisci-
plinary meeting, after weighing the pros and cons. A patient 
with PD-MCI or with prominent levodopa responsive non-
motor symptoms, for example, would probably get more 
benefit from the GPi as a target. In contrast, a patient with 
prominent medication-induced dyskinesias would be better 
treated with STN-DBS61,64.
Figure. Anatomic relationships between the DBS leads and the most common targets, STN and GPi. (A) The subthalamic nucleus 
(STN) is closely related to the substantia nigra (Sn), red nucleus and third nerve (ventromedial); zona incerta (dorsal), and internal 
capsule (lateral). (B) The internal globus pallidus [GPi] is closely related to the optic tract (ventral), internal capsule (medial and 
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CONCLUSION
In this article, we sought to address the complexity of ther-
apeutic decisions regarding the treatment of PD with DBS, call-
ing attention to the need to form dedicated multidisciplinary 
groups in order to optimize surgical outcomes. It is important 
to highlight that a group of features should be assessed before 
indicating DBS surgery, including not only the motor perfor-
mance or response to levodopa. The criteria involve several 
domains, passing through psychiatric and neuropsychological 
evaluation, associated with speech therapy, social and edu-
cational aspects. All of the domains are highly relevant to the 
final therapeutic decision, and it is not advised to conduct this 
therapy without a comprehensive assessment. A multidisci-
plinary team is essential to approach the parkinsonian patient 
in the DBS context, not only during the preoperative evalua-
tion but also during the follow-up.
This article is not intended to exhaust the discussion on 
this topic, but rather to stimulate rational, and therefore pos-
sibly more effective, surgical procedures.
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